For research use only. Not for therapeutic Use.
MIND4-17 is a potent NRF2 activator that covalently modifies a C151 residue of Keap1. MIND4-17 disrupts Keap1-Nrf2 association, leading to Nrf2 protein stabilization and nuclear translocation. MIND4‐17 exerts potent antioxidant activity[1][2].
MIND4-17 (0.1-2 μM; 24 hr) significantly and concentration-dependently increases the expression of the canonical ARE genes Nqo1, Hmox1, Srx1, and to a lesser degree Gclc[1].
MIND4-17 (0.1-2 μM; 24 hr) shows a concentration-dependent induction of NQO1 and GCLM proteins in both WT and HD mutant ST14A cells[1].
MIN4-17 (0.1-10 μM) reduces ROS levels and nitrogen intermediates production in microglia[1].
MIND4‐17 (2 mg/kg; intravitreal injection; once) activates Nrf2 signaling and attenuates retinal dysfunction by light damage in mice[2].
| Catalog Number | I042331 |
| CAS Number | 345989-24-4 |
| Synonyms | 5-nitro-2-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]pyridine |
| Molecular Formula | C20H15N5O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H15N5O3S/c26-25(27)16-11-12-19(21-13-16)29-20-23-22-18(14-28-17-9-5-2-6-10-17)24(20)15-7-3-1-4-8-15/h1-13H,14H2 |
| InChIKey | OZUBDKIROJPQGE-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)N2C(=NN=C2SC3=NC=C(C=C3)[N+](=O)[O-])COC4=CC=CC=C4 |
| Reference | [1]. Luisa Quinti, et al. SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington’s Disease Models. Cell Chem Biol. 2016 Jul 21;23(7):849-861. [2]. Nan Chen, et al. The Nrf2 activator MIND4-17 protects retinal ganglion cells from high glucose-induced oxidative injury. J Cell Physiol. 2020 Oct;235(10):7204-7213. |
